Vadodara (Gujarat)-based manufacturer of high-purity specialty fine chemicals — excipients, reagents and ingredients for pharmaceutical, nutraceutical and food applications.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 0 | 0 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 23 | 27 | 40 | 8 | 29 | 53 | 64 | 79 |
| Borrowings | 0 | 4 | 3 | 0 | 0 | 0 | 3 | 2 |
| Other Liabilities | 11 | 7 | 13 | 9 | 8 | 9 | 9 | 10 |
| Total Liabilities | 34 | 38 | 57 | 54 | 74 | 99 | 113 | 128 |
| AssetsFixed Assets | 6 | 9 | 11 | 16 | 26 | 28 | 30 | 29 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 29 | 28 | 45 | 38 | 47 | 70 | 82 | 98 |
| Total Assets | 34 | 38 | 57 | 54 | 74 | 99 | 113 | 128 |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 4 | 11 | 9 | 20 | 17 | 31 | 24 |
| Cash from Investing | -4 | -3 | -8 | -7 | -17 | -28 | -24 |
| Cash from Financing | 0 | -7 | -1 | -13 | 0 | -2 | 0 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 3 | 10 | 5 | 11 | 5 | 28 | 21 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (24.9×) and current (20.6×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 13.6% growth and a 21× exit, ₹153 only delivers your return if you pay ₹129. The price is currently baking in 17% growth.
EPS grows 13.6%/yr for 5 years, then fades to 6% over 2, exits at 21×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 13.6% | 8.44 |
| FY28 | 13.6% | 9.59 |
| FY29 | 13.6% | 10.89 |
| FY30 | 13.6% | 12.37 |
| FY31 | 13.6% | 14.06 |
| FY32 | 9.8% ·fade | 15.43 |
| FY33 | 6.0% ·fade | 16.36 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.